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Background: To investigate the relationship between P-glycoprotein (Pgp), glutathione S-transferase π (GST-π) and
topoisomerase II (Topo II) expression and human gastric cancer chemoresistance in vitro.
Methods: Primary single-cell suspensions were prepared from fresh specimens of primary gastric cancer and
exposed to hydroxycamptothecin (HCPT), cisplatin (CDDP), 5-fluorouracil (5-FU), adriamycin (ADM) and mitomycin
(MMC) for 48 h. Cell metabolic activity and rate of inhibition were evaluated using tetrazolium (MTT) assay. Pgp,
GST-π and Topo II expression was determined in gastric carcinoma tissue samples using immunohistochemistry.
Results: Chemosensitivity of the gastric cancer cells varied; the rates of inhibition of cells exposed to HCPT, CDDP and
5-FU were significantly higher than that of cells exposed to ADM and MMC (p < 0.05). Gastric cancer cells with Pgp
expression were resistant to ADM and HCPT (p = 0.008 and p = 0.011, respectively). Cells resistant to 5-FU, CDDP and
MMC had significantly higher GST-π expression (p < 0.05). Topo II expression was significantly lower in cells resistant to
HCPT, ADM and MMC (p < 0.05). Pgp and GST-π expression may contribute to primary resistance of gastric cancer cells
to some chemotherapeutic drugs, while Topo II expression may indicate HCPT, ADM and MMC sensitivity.
Conclusions: Pgp, GST-π and Topo II detection and the MTT assay could be used as predictors in chemotherapeutic
drug administration and for identifying drug resistance in gastric carcinoma.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
3448329111142964.
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Chemotherapy is an important element of systematic
treatment of malignant tumors, while the main obstacle to
effective chemotherapy is multidrug resistance (MDR).
There are two major mechanism of MDR. The first and
most important is transporter-based MDR caused by the
activation of transporter proteins such as P-glycoprotein
(Pgp) [1,2]; The second is non-transporter-based MDR,
which is caused by altered activity of enzyme systems such
as glutathione S-transferase π (GST-π), resulting in drug
sequestration in intracellular vesicles [3]. Reduced expres-
sion of topoisomerase II (Topo II) in cancer tissue was
closely related to MDR [4]. In this study, we cultured
primary gastric cancer cells from freshly resected gastric* Correspondence: lipeifeng00@hotmail.com
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stated.cancer specimens in vitro and assessed their sensitivity
to hydroxycamptothecin (HCPT), adriamycin (ADM), cis-
platin (CDDP), 5-fluorouracil (5-FU) and mitomycin
(MMC) by tetrazolium (MTT) colorimetric assay. Pgp,
GST-π and Topo II expression were examined by
immunohistochemical staining of paraffin-embedded gas-
tric cancer tissue specimens. The relationship between che-
moresistance and Pgp, GST-π and Topo II expression was
explored to clarify the related factors of primary drug re-
sistance in gastric cancer further.Materials and methods
Specimen collection and preparation
The study included 81 patients with primary gastric can-
cer; it was approved by the General Hospital of Jinan
Military Command Ethics Committee. The patients had
undergone gastrectomy at the hospital from Januarytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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firmed by pathology; tumor specimens without necrosis
were collected for primary culture. Single-cell suspen-
sions (1 × 105 cells/mL) were prepared [5]. All patients
provided written informed consent.MTT chemosensitivity assay
Gastric cancer cells were successfully cultured from 75
cases (93.75%). Aliquots (100 μL, 104 cells) were plated into
96-well microplates (Gibco, Carlsbad, CA, USA). Drug so-
lutions were dissolved in RPMI 1640 and 100-μL aliquots
were added to each well to yield final concentrations of
0.3 μg/mL HCPT (Sanlian Co. Ltd., Heilongjiang, China),
3.0 μg/mL CDDP (Qilu Co. Ltd., Shandong, China), 1.0 μg/
mL MMC (Huangshi Co. Ltd., Hubei, China), 50 μg/mL 5-
FU (Hualian Co. Ltd., Shanghai, China), or 4 μg/mL ADM
(Xinhua Co. Ltd., Shandong, China). Three duplicate wells
were plated for each specimen. Control wells contained
100 μL cell suspension, 100 μL RPMI 1640 and 10% fetal
bovine serum (FBS); 200 μL RPMI 1640 containing 10%
FBS was used as the blank control. Microplates were incu-
bated for 48 h at 37°C in a humidified atmosphere contain-
ing 5% CO2; 20 μL 0.4% MTT (Sigma-Aldrich, St. Louis,
MO, USA) and 0.1 M sodium succinate was added and the
microplates were incubated for a further 4 h at 37°C. The
optical densities of each well were determined using an
SM-3 easy reader (Tianshi, Beijing, China) at 570 nm. The
inhibition rates (IR) were calculated using the formula
(Ac–Ad)/(Ac–Ab) × 100%, where Ad, Ac and Ab represent
the mean absorbance of drug-treated, control and blank
wells, respectively. The results were defined as follows:
highly sensitive, IR > 50%; moderately sensitive, IR 30%–
50%; resistant, IR <30%.Table 1 MTT assay of 75 cases of primary gastric cancer
Drug Sensitivity Mean IR-Pgp, GST-π and Topo II expression in gastric cancer
Immunohistochemical staining for Pgp, GST-π and Topo
II was performed on formalin-fixed paraffin-embedded
tissue sections of gastric cancer using the streptavidin-
peroxidase method. All primary antibodies were pur-
chased from Maixin Biotechnology Lnc (Fuzhou, China).
The results were evaluated as previously described [6,7], i.
e., by counting 100 cells per field in 10 random fields
under high-magnification microscopy (×400, Olympus
BX53 [Olympus, Tokyo, Japan]). Positive staining was de-
fined as ≥25% staining; negative staining as <25% staining.High (%) Moderate (%) Low (%)
HCPT 7 (9.33) 25 (33.33) 43 (57.33) 40.6%※
CDDP 7 (9.39) 26 (34.67) 42 (56.00) 41.9%※
5-FU 9 (12.0) 29 (38.067) 37 (49.33) 43.4%※
ADM 4 (5.35) 27 (36.00) 44 (58.67) 31.6%
MMC 3 (4.00) 25 (33.33) 42 (62.67) 28.7%
※Compared with ADM and MMC: P < 0.05.Statistical analysis
Statistical analysis was carried out using SPSS v. 17.0 for
Windows; p-values were two-sided, and p < 0.05 was con-
sidered significant. Quantitative results were expressed as
mean ± standard error of the mean. Significant differences
were determined using the χ2 test and rank sum test.Results
Chemosensitivity assay
The MTT assay revealed that the drugs induced different
levels of inhibition in the tumor cells (Table 1). The IR
values in cells exposed to HCPT, CDDP and 5-FU were
similar and significantly higher than that of cells exposed
to ADM and MMC (rank sum test, p < 0.05).
Pgp, GST-π and Topo II expression in gastric cancer tissue
Pgp, GST-π and Topo II expression in gastric cancer
was determined by immunohistochemical staining. Pgp
expression was observed as brown-yellow particles in
the cytoplasm and plasmalemma; GST-π and Topo II
were visualized in the cytoplasm and nucleus, respect-
ively (Figure 1). The rates of positive Pgp, GST-π and
Topo II expression were 61.33% (46/75), 65.33% (49/75)
and 68.00% (51/75), respectively. There was no statis-
tical difference among the three proteins (p > 0.05).
Relationship between Pgp, GST-π and Topo II expression
and chemosensitivity
Tumor cells were considered chemosensitive if the IR
was ≥30% and chemoresistant if the IR was <30%. Cells
that expressed Pgp were resistant to HCPT and ADM (p <
0.05, Table 2), but not CDDP, 5-FU and MMC. Cells that
expressed GST-π were resistant to CDDP, 5-FU and MMC
(p < 0.05, Table 3). Topo II expression was related to sensi-
tivity to HCPT, ADM and MMC (p < 0.05, Table 4).
Discussion
Gastric cancer is one of the most common malignant tu-
mors worldwide [8]. Despite effective control of the pri-
mary tumor and the availability of both neoadjuvant and
adjuvant chemotherapy, it is currently the second lead-
ing cause of cancer death worldwide [9]. The poor prog-
nosis is associated with extensive local invasion, regional
lymph node metastasis, and chemoresistance [10]. Many
cancer cells develop intrinsic and acquired resistance
against chemotherapeutic agents structurally and mech-
anistically, thus chemotherapeutic complete response
cannot be obtained for the majority of malignant tu-
mors. Therefore, more studies on chemosensitivity and
chemoresistance have focused on various transporter
Figure 1 Immunohistochemical findings in gastric cancer tissue. (A) Positive Pgp staining in the cytoplasm and plasmalemma of tumor cells;
(B) Positive GST-π staining in the cytoplasm of tumor cells; (C) Positive Topo II staining in the nuclei of tumor cells.
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ally considered the major factor of chemotherapy failure
in patients with cancer [11,12]. In particular, overexpres-
sion or increased activity of the genes for Pgp and GST-π
and low Topo II expression are closely associated with
chemoresistance in many tumors. These proteins are in-
volved in chemoresistance via many mechanisms, includ-
ing increased drug efflux, decreased drug influx, drug
inactivation and drug target alteration [13].
Encoded by the MDR 1 (MDR1) gene and located
on 7q21.1, Pgp is a cell membrane-bound adenosine
triphosphate-binding cassette transporter that actively ex-
trudes a variety of chemotherapeutic drugs from cancer
cells [1], thereby possibly being responsible for intrinsic
and acquired drug resistance in numerous human cancers.
By pumping lipophilic drugs out of cells, Pgp reduces
intracellular drug concentrations and leads to drug re-
sistance [14]. Triller and coworkers found that in 17
chemotherapy-naive small cell lung cancer patients, che-
motherapy response was strongly associated with the level
of Pgp expression [15]. Low Pgp expression was associated
with good chemotherapy response, whereas higher expres-
sion predicted a worse outcome. Our study indicated that












Resistant 47some gastric cancer cases and that it was a participant and
mediator of gastric cancer cell resistance to ADM and
HCPT. ADM and HCPT are anthracycline and alkaloid
anti-cancer drugs, respectively; both are lipophilic drugs.
Pgp-positive gastric cancer cells exhibited obvious resist-
ance to ADM and HCPT, indicating that Pgp-positive gas-
tric cancer is likelier to be resistant to HCPT and ADM.
We believe that Pgp-related resistance mainly acts against
natural and lipophilic anti-cancer drugs, which is consist-
ent with the speculation of Pakos and Ioannidis [16].
Therefore, ADM and HCPT should not be recommended
to Pgp positive gastric cancer patients; rather, alkylating
agents and anti-metabolic drugs to which resistance is
not closely related with Pgp expression, would be more
appropriate.
GST-π, a member of the GST family, is a multifunctional
enzyme that plays a critical role in cellular detoxification by
catalyzing the conjugation of reduced glutathione to hydro-
phobic electrophilic compounds and may influence muta-
genesis and carcinogenesis. GST-π overexpression has been
observed in many tumors as compared to the surrounding
normal tissues and in various cancer cell lines resistant to
anti-cancer agents; GST-π has been used in cancer research
as a tumor biomarker [17]. Soh et al. found that nuclearitivity
Pgp expression χ2 P
itive(n) Negative(n)
15 17 6.271 0.011
31 12
20 13 0.722 0.641
26 16
22 16 0.629 0.824
24 13
11 20 9.350 0.008
35 9
17 11 0.883 0.527
29 18
Table 3 Relationship between GST-π expression and chemosensitivity
Drug Chemosensitivity Cases
(n)
GST-π expression χ2 P
Positive(n) Negative(n)
HCPT Sensitive 32 20 12 0.725 0.632
Resistant 43 29 14
CDDP Sensitive 33 15 18 8.122 0.013
Resistant 42 34 8
5-FU Sensitive 38 21 17 6.128 0.027
Resistant 37 28 9
ADM Sensitive 31 20 11 0.850 0.578
Resistant 44 29 15
MMC Sensitive 28 14 14 5.783 0.036
Resistant 47 35 12
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and acquired drug resistance in gynecological cancers,
which indicated that GST-π in malignant cells may be a
useful predictor and may contribute to anti-cancer drug
selection [18]. In our study, there was an obvious associ-
ation between GST-π expression and resistance to antibi-
otics (MMC), metal anti-cancer drugs (CDDP) and 5-FU
in chemotherapy-naïve patients, indicating that chemore-
sistance might occur in GST-π–positive gastric cancer.
Based on the mechanism of resistance, we hypothesize
that GST-π in combination with chemotherapy drugs and
drug detoxification may play a major role in early resist-
ance: higher GST-π expression, indicates lower cytotoxic
effects of chemotherapy drugs, leading to tumor cell
chemoresistance.
Topoisomerases are nuclear enzymes that play a key
role in DNA replication. Topo II localization in the nu-
cleus is involved in DNA transcription, translation and
replication. It can mediate DNA cleavage and the forma-
tion of DNA enzyme complexes during the S-G2/M
phase, which is an important target for a variety of












Resistant 47S-phase and appears to be the preferred target associ-
ated with drug resistance [19]. The mechanisms of Topo
II resistance are obviously different from that of Pgp and
GST-π, and reduction of its expression or alteration of
its properties would affect cross-linked DNA complex
formation and reduce chemosensitivity. In our study,
Topo II expression was significantly negatively corre-
lated with HCPT, ADM and MMC resistance, suggesting
that it is mainly involved in resistance to natural or
semi-natural and antibiotic anti-cancer drugs, indicating
the likelihood that Topo II negative gastric cancer would
be resistant to HCPT, ADM and MMC. Previously, we
demonstrated that the sensitivity of gastric cancer cells
to some chemotherapy drugs was associated with histo-
pathological type [5], suggesting that there is a greater
proportion of proliferative-phase (S-G2/M phase) cells in
poorly differentiated gastric cancer. In this phase, Topo
II expression is increased, therefore there would be a
high level of chemosensitivity to some of the drug effects
in proliferating cells. This is related to the relative clin-
ical sensitivity of poorly differentiated gastric cancer to
some chemotherapy drugs.ensitivity
Topo II expression χ2 P
itive(n) Negative(n)
27 5 9.224 0.009
24 19
23 10 0.787 0.635
28 14
29 9 2.326 0.149
26 11
26 5 7.250 0.015
25 19
25 3 6.843 0.019
26 21
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fered in gastric cancer, and the difference may be associ-
ated with the variation in sensitivity to HCPT, CDDP,
MMC, 5-FU and ADM. Pgp may be useful for predicting
intrinsic resistance to HCPT and ADM; GST-π for CDDP,
5-FU and MMC resistance; and Topo II may be useful
for predicting HCPT, ADM and MMC sensitivity. MDR
might be simultaneously involved in the participation of
multiple genes and molecular pathways. Combined identi-
fication of Pgp, GST-π and Topo II expression status may
be valuable for screening the most appropriate low-
toxicity and high-efficacy drugs prior to (neo)adjuvant
chemotherapy and optimizing the most effective individu-
alized chemotherapy regimens based on molecular bio-
logical mechanisms.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MG, LW and PFL carried out all evaluations and drafted the manuscript.
LW and XC performed the MTT chemosensitivity assay and
immunohistochemical examination. RXC collected the clinical data. PFL, MG
and LW contributed to the conception and design of the study. All authors
read and approved the final manuscript.
Acknowledgements
This work was partly supported by a grant from the President Fund of the
General Hospital of Jinan Military Command (No. 2013, to MG).
Author details
1Department of Pathology, General Hospital of Jinan Military Command,
Jinan, China. 2Department of Laboratory Diagnosis, General Hospital of Jinan
Military Command, Jinan, China.
Received: 23 October 2013 Accepted: 6 December 2013
Published: 10 December 2013
References
1. Perez-Tomas R: Multidrug resistance: retrospect and prospects in
anti-cancer drug treatment. Curr Med Chem 2006, 13(16):1859–1876.
2. Leonard GD, Fojo T, Bates SE: The role of ABC transporters in clinical
practice. Oncologist 2003, 8(5):411–424.
3. Zhang Y, Zhou T, Duan J, Xiao Z, Li G, Xu F: Inhibition of P-glycoprotein
and Glutathione S-transferase-pi mediated resistance by fluoxetine in
MCF-7/ADM cells. Biomed Pharmacother 2013, 67(8):757–762.
4. Ganapathi RN, Ganapathi MK: Mechanisms regulating resistance to
inhibitors of topoisomerase II. Front Pharmacol 2013, 4:89.
5. Wang L, Li PF, Geng M, Cao YC, Yin YC: Correlation between
chemosensitivity to anticancer drugs and telomerase reverse
transcriptase mRNA expression in gastric cancer. Diagn Pathol 2013, 8:33.
6. Liang ZY, Wang WZ, Gao J, Wu SF, Zeng X, Liu TH: Topoisomerase IIalpha
and HER2/neu gene alterations and their correlation in pancreatic ductal
adenocarcinomas. Zhonghua Bing Li Xue Za Zhi 2007, 36(2):102–106.
7. Liu X, Xiong H, Li J, He Y, Yuan X: Correlation of hK6 expression with
tumor recurrence and prognosis in advanced gastric cancer. Diagn
Pathol 2013, 8:62.
8. Guan Z, Zhang J, Song S, Dai D: Promoter methylation and expression of
TIMP3 gene in gastric cancer. Diagn Pathol 2013, 8(1):110.
9. Sotoudeh K, Hashemi F, Madjd Z, Sadeghipour A, Molanaei S, Kalantary E:
The clinicopathologic association of c-MET overexpression in Iranian
gastric carcinomas; an immunohistochemical study of tissue microarrays.
Diagn Pathol 2012, 7:57.
10. Jin J, Jin T, Quan M, Piao Y, Lin Z: Ezrin overexpression predicts the poor
prognosis of gastric adenocarcinoma. Diagn Pathol 2012, 7:135.
11. Pajic M, Iyer JK, Kersbergen A, van der Burg E, Nygren AO, Jonkers J, Borst P,
Rottenberg S: Moderate increase in Mdr1a/1b expression causes in vivoresistance to doxorubicin in a mouse model for hereditary breast cancer.
Cancer Res 2009, 69(16):6396–6404.
12. Pajeva IK, Sterz K, Christlieb M, Steggemann K, Marighetti F, Wiese M:
Interactions of the multidrug resistance modulators tariquidar and
Elacridar and their analogues with P-glycoprotein. Chem Med Chem 2013.
doi: 10.1002/cmdc.201300233. [Epub ahead of print]).
13. Longley DB, Johnston PG: Molecular mechanisms of drug resistance.
J Pathol 2005, 205(2):275–292.
14. Loscher W, Potschka H: Blood–brain barrier active efflux transporters:
ATP-binding cassette gene family. Neuro Rx 2005, 2(1):86–98.
15. Triller N, Korosec P, Kern I, Kosnik M, Debeljak A: Multidrug resistance in
small cell lung cancer: expression of P-glycoprotein, multidrug resistance
protein 1 and lung resistance protein in chemo-naive patients and in
relapsed disease. Lung Cancer 2006, 54(2):235–240.
16. Pakos EE, Ioannidis JP: The association of P-glycoprotein with response to
chemotherapy and clinical outcome in patients with osteosarcoma. A
meta-analysis. Cancer 2003, 98(3):581–589.
17. Gate L, Majumdar RS, Lunk A, Tew KD: Influence of glutathione
S-transferase pi and p53 expression on tumor frequency and spectrum
in mice. Int J Cancer 2005, 113(1):29–35.
18. Soh Y, Goto S, Kitajima M, Moriyama S, Kotera K, Nakayama T, Nakajima H,
Kondo T, Ishimaru T: Nuclear localisation of glutathione S-transferase pi is
an evaluation factor for drug resistance in gynaecological cancers.
Clin Oncol (R Coll Radiol) 2005, 17(4):264–270.
19. Nielsen D, Maare C, Skovsgaard T: Cellular resistance to anthracyclines.
Gen Pharmacol 1996, 27(2):251–255.
doi:10.1186/1746-1596-8-198
Cite this article as: Geng et al.: The association between chemosensitivity
and Pgp, GST-π and Topo II expression in gastric cancer. Diagnostic Pathology
2013 8:198.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
